Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Myoung Soo Kim  (Kim MS) 3 Articles
Clinical Study
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
Jaehyun Bae, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Hye Jin Wang, Myoung Soo Kim, Yu Seun Kim, Joong-Yeol Park, Eun Seok Kang
Endocrinol Metab. 2016;31(1):161-167.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.161
  • 6,336 View
  • 61 Download
  • 21 Web of Science
  • 21 Crossref
AbstractAbstract PDFPubReader   
Background

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes.

Methods

Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor.

Results

HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin.

Conclusion

Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes.

Citations

Citations to this article as recorded by  
  • Diabetic Kidney Disease in Post-Kidney Transplant Patients
    Ngoc-Yen T. Pham, Diego Cruz, Luis Madera-Marin, Raja Ravender, Pablo Garcia
    Journal of Clinical Medicine.2024; 13(3): 793.     CrossRef
  • International consensus on post-transplantation diabetes mellitus
    Adnan Sharif, Harini Chakkera, Aiko P J de Vries, Kathrin Eller, Martina Guthoff, Maria C Haller, Mads Hornum, Espen Nordheim, Alexandra Kautzky-Willer, Michael Krebs, Aleksandra Kukla, Amelie Kurnikowski, Elisabeth Schwaiger, Nuria Montero, Julio Pascual
    Nephrology Dialysis Transplantation.2024; 39(3): 531.     CrossRef
  • Metabolic Disorders in Liver Transplant Recipients: The State of the Art
    Filippo Gabrielli, Lucia Golfieri, Fabio Nascimbeni, Pietro Andreone, Stefano Gitto
    Journal of Clinical Medicine.2024; 13(4): 1014.     CrossRef
  • Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
    Lee-Moay Lim, Jer-Ming Chang, Hung-Tien Kuo
    Biomedicines.2023; 11(2): 470.     CrossRef
  • Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
    S. Elise Lawrence, Mary Moss Chandran, Jeong M. Park, Helen Sweiss, Thomas Jensen, Palak Choksi, Barrett Crowther
    Clinical Transplantation.2023;[Epub]     CrossRef
  • Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review
    Adnan Sharif
    Transplantation.2022; 106(12): 2301.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats
    Feng-Yen Lin, Chun-Min Shih, Chun-Yao Huang, Yi-Tin Tsai, Shih-Hurng Loh, Chi-Yuan Li, Cheng-Yen Lin, Yi-Wen Lin, Chien-Sung Tsai
    Cardiovascular Drugs and Therapy.2021; 35(6): 1111.     CrossRef
  • Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
    Sonya Anderson, Laura Cotiguala, Sarah Tischer, Jeong Mi Park, Katie McMurry
    Annals of Pharmacotherapy.2021; 55(4): 496.     CrossRef
  • Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
    Dora Oikonomaki, Evangelia Dounousi, Anila Duni, Stefanos Roumeliotis, Vassilios Liakopoulos
    Diabetes Research and Clinical Practice.2021; 172: 108604.     CrossRef
  • CD161a-positive natural killer (NK) cells and α-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection
    Franziska Schmid, Christina Mayer, Maike Büttner-Herold, Stephan von Hörsten, Kerstin Amann, Christoph Daniel
    Diabetes Research and Clinical Practice.2021; 173: 108691.     CrossRef
  • Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients
    Theerawut Klangjareonchai, Natsuki Eguchi, Ekamol Tantisattamo, Antoney J. Ferrey, Uttam Reddy, Donald C. Dafoe, Hirohito Ichii
    Pharmaceutics.2021; 13(3): 413.     CrossRef
  • Recent advances in new-onset diabetes mellitus after kidney transplantation
    Tess Montada-Atin, G V Ramesh Prasad
    World Journal of Diabetes.2021; 12(5): 541.     CrossRef
  • Safety and Efficacy of Long-Term Administration of Dipeptidyl peptidase IV Inhibitors in Patients With New Onset Diabetes After Kidney Transplant
    Adamantia Mpratsiakou, Marios Papasotiriou, Theodoros Ntrinias, Konstantinos Tsiotsios, Evangelos Papachristou, Dimitrios S. Goumenos
    Experimental and Clinical Transplantation.2021; 19(5): 411.     CrossRef
  • Medical management of metabolic and cardiovascular complications after liver transplantation
    Chiara Becchetti, Melisa Dirchwolf, Vanessa Banz, Jean-François Dufour
    World Journal of Gastroenterology.2020; 26(18): 2138.     CrossRef
  • Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis
    Tarek Samy Abdelaziz, Ahmed Yamany Ali, Moataz Fatthy
    Current Diabetes Reviews.2020; 16(6): 580.     CrossRef
  • NAFLD and liver transplantation: Disease burden, current management and future challenges
    Patrizia Burra, Chiara Becchetti, Giacomo Germani
    JHEP Reports.2020; 2(6): 100192.     CrossRef
  • Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study
    Rodolfo Guardado-Mendoza, David Cázares-Sánchez, María Lola Evia-Viscarra, Lilia M. Jiménez-Ceja, Edgar G. Durán-Pérez, Alberto Aguilar-García
    Diabetes Research and Clinical Practice.2019; 156: 107864.     CrossRef
  • Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
    Maria J. Peláez-Jaramillo, Allison A. Cárdenas-Mojica, Paula V. Gaete, Carlos O. Mendivil
    Diabetes Therapy.2018; 9(2): 521.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus
    Thomas Vanhove, Quinten Remijsen, Dirk Kuypers, Pieter Gillard
    Transplantation Reviews.2017; 31(2): 69.     CrossRef
  • Risk assessment and management of post-transplant diabetes mellitus
    Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
    Metabolism.2016; 65(10): 1559.     CrossRef
Close layer
Retraction: Contributing Factors to Different Natural Courses of Posttansplantation Diabetes Mellitus in Renal Allograft Recipients.
Kyu Yeon Hur, Myoung Soo Kim, Jae Hyun Nam, Eun Seok Kang, Hyun Joo Lee, So Hun Kim, Bong Soo Cha, Chul Woo Ahn, Soon Il Kim, Yu Seun Kim, Hyun Chul Lee
J Korean Endocr Soc. 2007;22(6):479.   Published online December 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.6.479
  • 1,680 View
  • 21 Download
PDF
Close layer
Contributing Factors to Different Natural Courses of Posttansplantation Diabetes Mellitus in Renal Allograft Recipients.
Kyu Yeon Hur, Myoung Soo Kim, Jae Hyun Nam, Eun Seok Kang, Hyun Joo Lee, So Hun Kim, Bong Soo Cha, Chul Woo Ahn, Soon Il Kim, Yu Seun Kim, Hyun Chul Lee
J Korean Endocr Soc. 2006;21(5):373-381.   Published online October 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.5.373
  • 2,246 View
  • 22 Download
  • 2 Crossref
AbstractAbstract PDF
BACKGROUND
New onset diabetes is a major complication after kidney transplantation. However, the natural course of posttransplantation diabetes mellitus (PTDM) remains unclear. The aim of this study was to demonstrate the detailed natural courses of PTDM according to the onset and persistency of hyperglycemia, and to investigate risk factors for development of different courses of PTDM in renal allograft recipients. METHODS: A total of 77 renal allograft recipients without previously known diabetes were enrolled and performed a serial 75 g oral glucose tolerance test at 0, 1, and 7 years after kidney transplantation. Patients were classified according to the onset and persistency of PTDM: early PTMD (E-PTDM), late PTDM (L-PTDM), persistent PTDM (P-PTDM), transient PTMD (T-PTDM), and non-PTDN (N-PTDM). RESULTS: The incidence of each group was as follows: E-PTDM, 39%; L-PTDM, 11.7%; P-PTDM, 23.4% T-PTDM, 15.6%; N-PTDM, 49.3%. Tacrolimus and female gender were associated with the development of E-PTDM. Among E-PTDM, age at transplantation was a high risk factor for the development of P-PTDM. Higher BMI at year1 was associated with the development of L-PTDM. CONCLUSION: Different risk factors were associated with various natural courses of PTDM. Since old age and female gender are not modifiable risk factors, it may be important to modify immunosuppressive therapy regimens for the prevention of E-PTDM and control of body weight for L-PTDM.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus
    Jaehyun Bae, Youjin Kim, Yongin Cho, Minyoung Lee, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Dong Jin Joo, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
    Transplantation Proceedings.2019; 51(10): 3444.     CrossRef
  • Post-transplantation Diabetes Mellitus
    Kun-Ho Yoon
    Journal of Korean Endocrine Society.2006; 21(5): 370.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP